The Canada-based medical marijuana company reported a net loss from continuing operations of C$75.1 million for the second quarter, compared to a loss of C$300.2 million in the prior-year quarter. Adjusted EBITDA loss was C$9 million, compared to C$11.2 million last year. Net revenues decreased 10% year-over-year to C$60.59 million.
“During the second quarter, we improved our Adjusted EBITDA by $2.5 million over Q1, moving us closer to our profitability goal. Our focus remains on further cost reductions, and we are pleased to announce today that we expect to reach the high end of the $60 to $80 million range. Our balance sheet remains among the strongest in the industry, with approximately $445 million in cash as of yesterday, ” said Miguel Martin, chief executive officer of Aurora Cannabis.
Read management/analysts’ comments on Aurora’s Q2 results
Shares of Aurora Cannabis gained soon after the earnings release on Thursday evening at the New York Stock Exchange, after closing the regular session higher.
